Cisplatin and TRAIL enhance breast cancer stem cell death.

摘要: Triple negative breast cancer (TNBC) has increased recurrence and poor survival, despite a high response rate to neoadjuvant chemotherapy. The aim of this study was determine whether current drug treatment(s) eliminates bulk tumor cells, but it minimal effect on stem cells (CSCs) leading recurrence. We studied the effects PARP inhibitors (AZD2281 BSI-201), paclitaxel, docetaxel, cisplatin plus TRAIL CSCs derived from CRL-2335 MDA-MB-468 TNBC in vitro. vitro data indicate that TRIAL treatment most effective eliminating compared inhibitors, cisplatin, paclitaxel docetaxel. Treatment with also inhibits Wnt-1 signaling its downstream target, β-catenin, phospho cyclin D1, apoptosis, reduced proliferation mammosphere formation. Inhibition by siRNA significantly ability form mammospheres control. However, maximum seen TRAIL-treated cells. Taken together suggest potential providing new strategy for improving therapeutic outcome patients.